DrotAA treatment improved protein C levels by day 1 compared with placebo (P = 0.008)
treatment with drotrecogin alfa (activated) (DrotAA) in  severe deficiency, protein C levels ≤ 40% of normal protein C activity (n = 615, 39% of patients); deficient, protein C levels 41–80% of normal protein C activity (n = 764, 48.5% of patients);
treatment with drotrecogin alfa (activated) (DrotAA) in  &gt;80% of normal protein C activity (n = 195, 12.4% of patients)
protein S and antithrombin III